Genomic Health (NASDAQ:GHDX) updated its FY19 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.38-1.54 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.25. The company issued revenue guidance of $436-448 million, compared to the consensus revenue estimate of $439.74 million.
GHDX has been the subject of a number of recent research reports. Needham & Company LLC increased their target price on Genomic Health from $86.00 to $97.00 and gave the stock a strong-buy rating in a report on Thursday. Piper Jaffray Companies raised their price objective on Genomic Health to $86.00 and gave the stock a neutral rating in a research note on Thursday. ValuEngine cut Genomic Health from a strong-buy rating to a buy rating in a report on Tuesday, December 11th. Canaccord Genuity reiterated a buy rating and set a $82.00 price target (up previously from $70.00) on shares of Genomic Health in a report on Wednesday, November 7th. Finally, Oppenheimer initiated coverage on shares of Genomic Health in a research report on Wednesday, December 19th. They issued a market perform rating for the company. Nine equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company. Genomic Health has an average rating of Buy and a consensus price target of $63.13.
NASDAQ GHDX traded down $5.31 during trading hours on Thursday, hitting $78.35. 1,008,519 shares of the company’s stock traded hands, compared to its average volume of 344,894. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of 7,835.00 and a beta of 0.88. Genomic Health has a 52 week low of $30.04 and a 52 week high of $92.18.
In other news, CEO Kimberly J. Popovits sold 47,900 shares of the business’s stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $81.70, for a total transaction of $3,913,430.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO G Bradley Cole sold 15,000 shares of the business’s stock in a transaction dated Tuesday, February 12th. The shares were sold at an average price of $80.87, for a total transaction of $1,213,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,177,707 shares of company stock valued at $161,807,112 over the last three months. 45.80% of the stock is currently owned by insiders.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Featured Story: Trading Ex-Dividend
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.